- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01977300
Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomised, double-blind, placebo controlled trial over 52 weeks. Patients will be on one of four combinations of medications at the time of entry into the study: a) lithium and risperidone, b) lithium and olanzapine, c) valproate and risperidone, or d) valproate and olanzapine. After obtaining informed consent, patients will be randomised to one of three groups 1)"0" week group: patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomisation with discontinuation of the drug within 2 weeks), 2) continuation of the same atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 24 weeks (tapering of the antipsychotic begins at the end of 24 weeks and completed within 2 weeks) followed by the same mood stabilizer plus placebo for another 28 weeks, and 3) continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks. The duration of the double-blind phase of the study will be 52 weeks and all patients will continue on the mood stabilizer, lithium or valproate, they had been on during the acute mania for the full duration of the study. The serum level of the mood stabilizer will be maintained within the therapeutic range (0.6 to 1.2 mmol/L for lithium and 50 to 125 ug/L for valproate) throughout the 52 weeks as determined by blood tests. The dose and the type of atypical antipsychotic (ie risperidone or olanzapine) each patient will receive during the double-blind period will be the same that the patient had been on at the time of entry into the double-blind phase. All patients, irrespective of which treatment arm they are in, will receive active psychoeducation and counselling regarding sleep hygiene, healthy daily routines and rhythms, alcohol and substance abuse, anxiety management, conflict resolution and problem solving as clinically indicated in routine clinical practice. Patients who withdraw from or meet a primary end point of the study will be treated actively as done in regular clinical practice.
Patients will not be allowed to receive any other psychotropic medication with the exception of benzodiazepines for sedation and anti-parkinsonian medication for extrapyramidal side effects. The doses of these will be recorded.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 2A1
- University of British Columbia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who were recently (within the last 12 weeks) commenced on treatment for a Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) manic or mixed episode with a combination of lithium and risperidone, lithium and olanzapine, valproate and risperidone, or valproate and olanzapine;
- Patients on 1 to 6 mg of risperidone or 5 to 25 mg of olanzapine
- Patients who are in remission from mania for at least 2 weeks but no more than 6 weeks and have maintained remission for 2 consecutive weeks;
- Patients must not be taking any other psychotropic medication (with the exception of benzodiazepines) or treatments including bromocriptine, omega 3 fatty acids, Axid or EMPower;
- Patients aged 17 and above.
Exclusion Criteria:
- Any subjects who do not meet the above inclusion criteria will be excluded from the study.
- In order for the findings to be generalizable to clinically representative patients with bipolar disorder, any patients with a history of co-morbid substance abuse or medical illnesses will not be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Mood stabilizer & Placebo
Patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomization with discontinuation of the drug within 2 weeks).
|
serum level of 50 to 125 ug/L
Other Names:
serum levels of 0.6 to 1.2 mmol/L
Other Names:
manufactured to mimic risperidone and olanzapine
Other Names:
|
EXPERIMENTAL: '24 week " arm
Continuation of the lithium or valproate plus risperidone or olanzapine for 24 weeks followed by mood stabilizer plus placebo for another 28 weeks.
Dosages: 1 to 6 mg of risperidone, 5 to 20 mg olanzapine.
|
serum level of 50 to 125 ug/L
Other Names:
serum levels of 0.6 to 1.2 mmol/L
Other Names:
manufactured to mimic risperidone and olanzapine
Other Names:
1 to 6 mg/day
Other Names:
5 to 25 mg/day
Other Names:
|
ACTIVE_COMPARATOR: "52 week" arm
Continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks.
|
serum level of 50 to 125 ug/L
Other Names:
serum levels of 0.6 to 1.2 mmol/L
Other Names:
1 to 6 mg/day
Other Names:
5 to 25 mg/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome measure is the time to any mood episode (depressive or manic episode).
Time Frame: 52 weeks
|
A mood episode is defined as 1) Young Mania Rating Scale (YMRS) score of 15 or greater 2)Hamilton Rating Scale for Depression (HAM-D) 21-item score of 15 or greater or a HAM-D suicide item score of 3 or greater 3)A Clinical Global Impression -Severity (CGI-S) score of 3 or greater 4) a patient requiring hospitalization for treatment of mood symptoms or 5) a patient who makes a suicide attempt or commits suicide during the study.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to manic episode.
Time Frame: 52 weeks
|
Time to occurrence of a manic episode measured by Young Mania Rating Scale (YMRS) score of 15 or greater .
|
52 weeks
|
Time to depressive episode
Time Frame: 52 weeks
|
Time to occurrence of a depressive episode measured by Hamilton Rating Scale for Depression (HAM-D) 21-item score of 15 or greater or a HAM-D suicide item score of 3 or greater.
|
52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lakshmi N Yatham, Dr., University of British Columbia
- Study Director: Serge Beaulieu, Dr., McGill University, Montreal
- Study Director: Andree Daigneault, Dr., Clinique des Maladies Affectives, Montreal
- Study Director: Verinder Sharma, Dr., Regional Mental Health Care London, Ont.
- Study Director: Hubert Wong, Dr., University of British Columbia
- Study Director: Ayal Schaffer, Dr., Sunnybrook Health Sciences Centre, Toronto, Ont.
- Study Director: Sagar Parikh, Dr., Centre for Addiction and Mental Health, Toronto, Ont.
- Study Director: Philippe Baruch, Dr., Clinique des troubles de l'humeur, Quebec
- Study Director: Peter Silverstone, Dr., University of Alberta
- Study Director: Roumen Milev, Dr., Providence Continuing Care, Kingston, Ont.
- Study Director: Ram Veluri, Dr., Northern Health Research Inc., Sudbury, Ont.
- Study Director: Pablo Cervantes, Dr., Montreal General, Quebec
- Study Director: Claire O'Donovan, Dr., Mental Health Services, Halifax, NS
- Study Director: Flavio Kapczinski, Dr., Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
- Study Director: Benny Lafer, Dr., Instituto de Psiquiatria do Hospital das Clínicas, Sao Paulo, Brazil
- Study Director: Angelo B Miralha da Cunha, Dr., Santa Maria, Brazil
- Study Director: Joao Quevedo, Dr., Casa de Saude do Rio Maina Ltda, Criciuma, Brazil
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Mania
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Olanzapine
- Valproic Acid
- Risperidone
- Lithium Carbonate
Other Study ID Numbers
- H02-70188
- V02-0130 (OTHER: Vancouver Coastal Health Research Institute)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar I Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedBipolar I DisorderUnited States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
-
Professor Saad ShakirMerck Sharp & Dohme LLCCompletedBipolar I DisorderUnited Kingdom
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompleted
-
University of Sao PauloCompleted
-
University of Sao PauloUnknown
-
Merck Sharp & Dohme LLCRecruitingBipolar I DisorderUnited States
-
Roxane LaboratoriesCompletedBipolar I DisorderUnited States
-
Eli Lilly and CompanyCompletedBipolar I DisorderUnited States
Clinical Trials on Valproate
-
Ewha Womans UniversityWithdrawnBipolar DepressionKorea, Republic of
-
University of BirminghamActive, not recruitingWolfram SyndromeFrance, United Kingdom, Poland, Spain
-
Ewha Womans University Mokdong HospitalWithdrawnDepression, BipolarKorea, Republic of
-
Xijing HospitalUnknownTraumatic Brain InjuryChina
-
All India Institute of Medical Sciences, New DelhiUnknownChronic Lymphocytic LeukemiaIndia
-
University of VirginiaTerminatedGlioblastomaUnited States
-
Postgraduate Institute of Dental Sciences RohtakUnknownAlveolar Bone LossIndia
-
M.D. Anderson Cancer CenterCancer Prevention Research Institute of TexasEnrolling by invitationDelirium | Epileptics | NeurolepticsUnited States